Trial Profile
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS (GRACE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Sargramostim (Primary)
- Indications Sepsis
- Focus Therapeutic Use
- Acronyms GRACE
- 07 Feb 2023 Planned End Date changed from 5 Dec 2022 to 5 Dec 2023.
- 07 Feb 2023 Planned primary completion date changed from 5 Dec 2022 to 5 Dec 2023.
- 24 Feb 2022 Planned End Date changed from 5 Dec 2021 to 5 Dec 2022.